225 results on '"Villeval, Jean-Luc"'
Search Results
2. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes
3. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene
4. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms
5. Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation
6. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes
7. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines
8. Activating mutations in human acute megakaryoblastic leukemia
9. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
10. Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis
11. In VitroandIn VivoInteractions between Stromal and Leukemic Cells
12. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells
13. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen
14. Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage
15. Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease
16. Predicting the Long-Term Efficacy of Ifnα in JAK2V617F and Calr-Mutated MPN Patients
17. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily
18. Hematopoietic-specific β1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2
19. Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN
20. Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic
21. Pathophysiology of Thrombocytopenia and Anemia in Mice Lacking Transcription Factor NF-E2
22. HSP27: A Therapeutic Target in Myelofibrosis
23. Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models
24. Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms
25. Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis
26. Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms
27. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis
28. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
29. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
30. Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis
31. The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms
32. Use Of 46/1 Haplotype Permits To Follow JAK2V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment
33. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
34. 46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2V617F clonal Architecture in PV Patients
35. Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease
36. Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms
37. The Cell Cycle Regulator CDC25A Is a Target for JAK2V617F Oncogene
38. Platelet Phenotype and Thrombosis In JAK2V617F Mice
39. JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect
40. Novel Mutations: Dissecting Pathogenetic Contribution
41. Interferon-Alpha Preferentially Targets JAK2V617F-Positive Rather Than Wild-Type Early Progenitor Cells in Myeloproliferative Disorders.
42. Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice.
43. Ligand-Independent MPLW515L Activity Requires Cell Surface Localization
44. Increased Myelofibrosis in Thrombospondin-1-Null Mice Is Associated with Enhanced TGF-β1-Mediated Response by Bone Marrow Fibroblasts
45. JAK2 Activation Stimulates Homologous Recombination and Genetic Instability.
46. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
47. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
48. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
49. Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis.
50. Human Platelet Glycoprotein VI: Identification of Residues Involved in the Binding to Collagen.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.